Enhancing cytokine-induced killer cell therapy of multiple myeloma

Experimental Hematology

Volumn 41, Issue 6, 2013, Pages 508-517

  Liu, Chunsheng ^a   Suksanpaisan, Lukkana ^a   Chen, Yun Wen ^a   Russell, Stephen J ^a   Peng, Kah Whye ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D; ONCOLYTIC MEASLES VIRUS; ONCOLYTIC VIRUS; PROTEIN MICA; PROTEIN MICB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; COCULTURE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOLYSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; IONIZING RADIATION; MEASLES VIRUS; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; WHOLE BODY RADIATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELLS, CULTURED; COCULTURE TECHNIQUES; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MEASLES VIRUS; MICE; MICE, INBRED ICR; MICE, SCID; MULTIPLE MYELOMA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; ONCOLYTIC VIROTHERAPY; RANDOM ALLOCATION; RNA, MESSENGER; STROMAL CELLS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MEASLES VIRUS; MUS;

EID: 84878200376     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.01.010     Document Type: Article

References (66)

1. Morgan G.J., Walker B.A., Davies F.E. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012, 12:335-348.
2. Chesi M., Bergsagel P.L. Many multiple myelomas: making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program 2011, 2011:344-353.
3. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, (62):10-29.
4. Laport G.G., Sheehan K., Baker J., et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1679-1687.
5. Dimopoulos M.A., San-Miguel J.F., Anderson K.C. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 2011, 86:1-15.
6. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2011, 2:363-368.
7. Zafirova B., Wensveen F.M., Gulin M., Polic B. Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Molecular Life Sci 2011, 68:3519-3529.
8. Jamieson A.M., Diefenbach A., McMahon C.W., Xiong N., Carlyle J.R., Raulet D.H. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002, 17:19-29.
9. Diefenbach A., Jamieson A.M., Liu S.D., Shastri N., Raulet D.H. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000, 1:119-126.
10. Obeidy P., Sharland A.F. NKG2D and its ligands. Int J Biochem Cell Biol 2009, 41:2364-2367.
11. Eagle R.A., Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007, 7:737-744.
12. Champsaur M., Lanier L.L. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010, 235:267-285.
13. Linn Y.C., Hui K.M. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 2010, 2010:435745.
14. Li X.D., Xu B., Wu J., et al. Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol 2012, 14:102-108.
15. Ma Y., Zhang Z., Tang L., et al. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 2012, 14:483-493.
16. Thanendrarajan S., Nowak M., Abken H., Schmidt-Wolf I.G. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: More than one plus one?. Leuk Res 2011, 35:1136-1142.
17. Russell S.J., Peng K.W., Bell J.C. Oncolytic virotherapy. Nat Biotechnol 2012, 30:658-670.
18. Eager R.M., Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther 2011, 18:305-317.
19. Pesonen S., Kangasniemi L., Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 2011, 8:12-28.
20. Lech P.J., Russell S.J. Use of attenuated paramyxoviruses for cancer therapy. Expert Rev Vaccines 2010, 9:1275-1302.
21. Dorig R.E., Marcil A., Chopra A., Richardson C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993, 75:295-305.
22. Tatsuo H., Ono N., Tanaka K., Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000, 406:893-897.
23. Muhlebach M.D., Mateo M., Sinn P.L., et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011, 480:530-533.
24. Noyce R.S., Richardson C.D. Nectin 4 is the epithelial cell receptor for measles virus. Trends Microbiol 2012, 20:429-439.
25. Blechacz B., Splinter P.L., Greiner S., et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 2006, 44:1465-1477.
26. Liu C., Russell S.J., Peng K.W. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 2010, 18:1155-1164.
27. Myers R.M., Greiner S.M., Harvey M.E., et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007, 82:700-710.
28. Dingli D., Peng K.W., Harvey M.E., et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004, 103:1641-1646.
29. Duprex W.P., McQuaid S., Hangartner L., Billeter M.A., Rima B.K. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 1999, 73:9568-9575.
30. Mader E.K., Maeyama Y., Lin Y., et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009, 15:7246-7255.
31. Lu P.H., Negrin R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994, 153:1687-1696.
32. Hadac E.M., Peng K.W., Nakamura T., Russell S.J. Reengineering paramyxovirus tropism. Virology 2004, 329:217-225.
33. Tamura H., Ishibashi M., Yamashita T., et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2012, 27:464-472.
34. Scuto A., Krejci P., Popplewell L., et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 2011, 25:538-550.
35. Tannous B.A. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat Protoc 2009, 4:582-591.
36. Kapoor P., Rajkumar S.V. Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int J Hematol 2011, 94:310-320.
37. Engelhardt M., Kleber M., Udi J., et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 2010, 51:1424-1443.
38. Mahindra A., Laubach J., Raje N., Munshi N., Richardson P.G., Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012, 9:135-143.
39. Johnson S.K., Heuck C.J., Albino A.P., et al. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int J Hematol 2011, 94:321-333.
40. Stief A.E., McCart J.A. Oncolytic virotherapy for multiple myeloma. Expert Opin Biol Ther 2008, 8:463-473.
41. Mitsiades C.S., Davies F.E., Laubach J.P., et al. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 2011, 29:1916-1923.
42. Rosenblatt J., Avigan D. Cellular immunotherapy for multiple myeloma. Best Pract Res Clin Haematol 2008, 21:559-577.
43. Szmania S., Tricot G., van Rhee F. NY-ESO-1 immunotherapy for multiple myeloma. Leuk Lymphoma 2006, 47:2037-2048.
44. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., Weissman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991, 174:139-149.
45. Leemhuis T., Wells S., Scheffold C., Edinger M., Negrin R.S. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005, 11:181-187.
46. Shi J., Tricot G., Szmania S., et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008, 143:641-653.
47. Moretta L., Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004, 23:255-259.
48. Shi M., Zhang B., Tang Z.R., et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004, 10:1146-1151.
49. Lin J., Zhu H., Lu X., et al. Autologous cytokine-induced killer cells in the treatment of multiple myeloma concomitant with lung cancer and paraneoplastic dermatoses. Intern Med 2010, 49:2341-2346.
50. Su X., Zhang L., Jin L., Ye J., Guan Z., Chen R. Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells. J Clin Immunol 2010, 30:766-774.
51. Marten A., Renoth S., von Lilienfeld-Toal M., et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 2001, 86:1029-1037.
52. Lu X., Zhu A., Cai X., et al. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells. Cancer Biol Ther 2012, 13:623-629.
53. Verneris M.R., Baker J., Edinger M., Negrin R.S. Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. J Clin Immunol 2002, 22:131-136.
54. Shi J., Tricot G.J., Garg T.K., et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 2008, 111:1309-1317.
55. Westendorf J.J., Ahmann G.J., Greipp P.R., Witzig T.E., Lust J.A., Jelinek D.F. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 1996, 10:866-876.
56. Zhong R., Teng J., Han B., Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 2011, 60:1497-1502.
57. Thorne S.H., Negrin R.S., Contag C.H. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006, 311:1780-1784.
58. Thorne S.H., Contag C.H. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery. Gene Ther 2008, 15:753-758.
59. Ong H.T., Hasegawa K., Dietz A.B., Russell S.J., Peng K.W. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 2007, 14:324-333.
60. Iankov I.D., Blechacz B., Liu C., et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Molecular Ther 2007, 15:114-122.
61. Peng K.W., Dogan A., Vrana J., et al. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol 2009, 84:401-407.
62. Munguia A., Ota T., Miest T., Russell S.J. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Therapy 2008, 15:797-806.
63. Groh V., Rhinehart R., Randolph-Habecker J., Topp M.S., Riddell S.R., Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001, 2:255-260.
64. Ishikawa E., Tsuboi K., Saijo K., Takano S., Ohno T. X-irradiation to human malignant glioma cells enhances the cytotoxicity of autologous killer lymphocytes under specific conditions. Int J Radiat Oncol Biol Phys 2004, 59:1505-1512.
65. Sumareva R., Ukrainsky G., Kiremidjian-Schumacher L., et al. Effect of combined adoptive immunotherapy and radiotherapy on tumor growth. Radiat Oncol Investig 1999, 7:22-29.
66. Kim J.Y., Son Y.O., Park S.W., et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med 2006, 38:474-484.